European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility

British Journal of Anaesthesia

Volumn 115, Issue 4, 2015, Pages 531-539

  Hopkins, P M ^a   Ruffert H ^b,c   Snoeck, M M ^d   Girard, T ^e   Glahn, K P E ^f   Ellis, F R ^a   Muller C R ^g   Urwyler, A ^e   Bandschapp, O ^h   Gillies, R ⁱ   Glauber, V ^j   Heytens, L ^k   Islander, G ^l   Klingler, W ^m   Kraft, B ⁿ   Krivosic Horber, R ^o   Pollock, N ^p   Schuster, F ^q   Silva, H ^r   Sorrentino, V ^s   Street, N ^t   Tegazzin, V ^u   Tzanova, I ^v   more..

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c Helios Klinik Schkeuditz   (Germany)

^d CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^e UNIVERSITY OF BASEL   (Switzerland)

^f GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^g UNIVERSITY OF WÜRZBURG   (Germany)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁱ ROYAL MELBOURNE HOSPITAL   (Australia)

^j SHEBA MEDICAL CENTER   (Israel)

^k ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^l LUND UNIVERSITY HOSPITAL   (Sweden)

^m UNIVERSITY HOSPITAL ULM   (Germany)

ⁿ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^o LILLE UNIVERSITY HOSPITAL   (France)

^p PALMERSTON NORTH HOSPITAL   (New Zealand)

^q UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^r FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^s UNIVERSITY OF SIENA   (Italy)

^t CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^u Hospital San Antonio   (Italy)

^v Christophorus Kliniken   (Germany)

more..

Author keywords

CACNA1S; diagnosis; excitation contraction coupling; malignant hyperthermia; malignant hyperthermia susceptibility; RYR1; skeletal muscle

Indexed keywords

CREATINE KINASE;

ARTICLE; CLINICAL PROTOCOL; CREATINE KINASE BLOOD LEVEL; DISEASE PREDISPOSITION; GENERAL ANESTHESIA; GENETIC ANALYSIS; GENETIC MANIPULATION; GENETIC SCREENING; HETEROLOGOUS EXPRESSION; HUMAN; IN VITRO CONTRACTURE TEST; IN VITRO STUDY; MALIGNANT HYPERTHERMIA; MUSCLE BIOPSY; MUSCULOSKELETAL SYSTEM EXAMINATION; PATIENT REFERRAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHABDOMYOLYSIS; SUDDEN INFANT DEATH SYNDROME; EUROPE; GENETIC PREDISPOSITION; GENETICS;

EUROPE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALIGNANT HYPERTHERMIA; REFERRAL AND CONSULTATION;

EID: 84943246453     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aev225     Document Type: Review

References (56)

1. Ellis FR. European Malignant Hyperpyrexia Group. Br J Anaesth 1984; 56: 1181-2
2. Kalow W, Britt BA, Terreau ME, Haist C. Metabolic error of muscle metabolism after recovery from malignant hyperthermia. Lancet 1970; 2: 895-8
3. Ellis FR, Keaney NP, Harriman DG, et al. Screening for malignant hyperpyrexia. Br Med J 1972; 3: 559-61
4. The European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 1984; 56: 1267-9
5. LarachMG, Localio AR,AllenGC, et al.Aclinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80: 771-9
6. Ording H, Brancadoro V, Cozzolino S, et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the EuropeanMHGroup: results of testing patients surviving fulminantMHand unrelated low-risk subjects. Acta Anaesthesiol Scand 1997; 41: 955-66
7. McCarthy TV, Healy JM, Heffron JJ, et al. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature 1990; 342: 562.4
8. MacLennan DH, Duff C, Zorzato F, et al. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 1990; 343: 559-61
9. Levitt RC, Olckers A, Meyers S, et al. Evidence for the localization of a malignant hyperthermia susceptibility locus (MHS2) to human chromosome 17q. Genomics 1992; 14: 562-6
10. Iles DE, Lehmann-Horn F, Scherer SW, et al. Localization of the gene encoding the 2/-subunits of the L-type voltagedependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families. Hum Mol Genet 1994; 3: 969-75
11. Robinson R, Monnier N,WolzW, et al. A genome-wide search for susceptibility loci in two European malignant hyperthermia pedigrees. Hum Mol Genet 1997; 6: 953-61
12. Deufel T, Sudbrak R, Feist F, et al. Discordance in a malignant hyperthermia pedigree between in vitro contracture test phenotypes and haplotypes for the MHS1 region on chromosome 19q12-13.2 comprising the C1840T transition in the RYR1 gene. Am J Hum Genet 1995; 56: 1334.42
13. Adeokun AM,West SP, Ellis FR, et al. The G1021A substitution in the RYR1 gene does not cosegregate with malignant hyperthermia susceptibility in a British pedigree. Am J Hum Genet 1997; 60: 833-41
14. Monnier N, Procaccio V, Stieglitz P, Lunardi J. Malignanthyperthermia susceptibility is associated with a mutation of the 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet 1997; 60: 1316-25
15. Robinson RL, Curran JL, Ellis FR, et al. Multiple interacting gene products may influence susceptibility to malignant hyperthermia. Ann Hum Genet 2000; 64: 307-20
16. Robinson RL, Hopkins PM, Carsana A, et al. Several interacting genes influence the malignant hyperthermia phenotype. Hum Genet 2003; 112: 217-8
17. Schiemann AH, Durholt EM, Pollock N, Stowell KM. Sequence capture and massively parallel sequencing to detect mutations associated with malignant hyperthermia. Br J Anaesth 2013; 110: 122-7
18. Kim JH, Jarvik GP, Browning BL, et al. Exome sequencing reveals novel rare variants in the ryanodine receptor and calcium channel genes in malignant hyperthermia families. Anesthesiology 2013; 119: 1054-65
19. Urwyler A, Deufel T, McCarthy T, West S. Guidelines for the molecular detection of susceptibility to malignant hyperthermia. Br J Anaesth 2001; 86: 283-7
20. Robinson RL, Anetseder MJ, Brancadoro V, et al. Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing? Eur J Hum Genet 2003; 11: 342-8
21. Denborough MA, Galloway GJ, Hopkinson KC. Malignant hyperpyrexia and sudden infant death. Lancet 1982; 2: 1068-9
22. Brownell AK. Malignant hyperthermia: relationship to other diseases. Br J Anaesth 1988; 60: 330-8
23. Wappler F, Fiege M, Steinfath M, et al. Evidence for susceptibility to malignant hyperthermia in patients with exercise-induced rhabdomyolysis. Anesthesiology 2001; 94: 95-100
24. Diamini N, Voermans NC, Lillis S, et al. Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis. Neuromuscul Disord 2013; 23: 540-8
25. Isaacs H, Barlow MB. Malignant hyperpyrexia during anaesthesia: possible association with subclinical myopathy. Br Med J 1970; 1: 275-7
26. Ellis FR, Clarke IM, Modgill M, Currie S, Harriman DG. Evaluation of creatine phosphokinase in screening patients for malignant hyperpyrexia. Br Med J 1975; 3: 511-3
27. Weglinski MR, Wedel DJ, Engel AG. Malignant hyperthermia testing in patients with persistently increased serum creatine kinase levels. Anesth Analg 1997; 84: 1038-41
28. Hopkins PM, Ellis FR, Halsall PJ. Evidence for related myopathies in exertional heat stroke and malignant hyperthermia. Lancet 1991; 338: 1491-2
29. Bendahan D, Kozak-Ribbens G, Confort-Gouny S, et al. A noninvasive investigation of muscle energetics supports similarities between exertional heat stroke and malignant hyperthermia. Anesth Analg 2001; 93: 683-9
30. Tobin JR, Jason DR, Nelson TE, Sambuughin N. Malignant hyperthermia and apparent heat stroke. JAMA 2001; 286: 168-9
31. Hopkins PM. Is there a link between malignant hyperthermia and exertional heat illness? Br J Sports Med 2007; 41: 283-4
32. Grogan H, Hopkins PM. Heat stroke: implications for critical care and anaesthesia. Br J Anaesth 2002; 88: 700-7
33. European Malignant Hyperpyrexia Group. Laboratory diagnosis of malignant hyperpyrexia susceptibility (MHS). Br J Anaesth 1985; 57: 1038
34. Hopkins PM, Halsall PJ, Ellis FR, Stewart AD. An analysis of the predictive probability of the in vitro contracture test for determining malignant hyperthermia susceptibility. Anesth Analg 1997; 84: 648-56
35. Ginz HF, Ruffert H, Levano S, et al. A mathematical model to improve on phenotyping for molecular genetic research in malignant hyperthermia. Pharmacogenet Genomics 2009; 19: 972-8
36. Carpenter D, Robinson RL, Quinnell RJ, et al. Genetic variation in RYR1 and malignant hyperthermia phenotypes. Br J Anaesth 2009; 103: 538-48
37. Monnier N, Krivosic-Horber R, Payen JF, et al. Presence of two different genetic traits in malignant hyperthermia families: implications for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. Anesthesiology 2002; 97: 1067-74
38. Wallis Y, Payne S, McAnulty C, et al. Practice guidelines for the evaluation of pathogenicity and the reporting of sequence variants in clinical molecular genetics. Association for Clinical Genetic Science and the Dutch Society of Clinical Genetic Laboratory Specialists 2013. Available from http://www.acgs.uk. com/media/774853/evaluation-and-reporting-of-sequence-variants-bpgs-june-2013-finalpdf.pdf (accessed 5 November 2014)
39. Moller P, Clark N, Mahle L. A simplified method for segregation analysis (SISA) to determine penetrance and expression of a genetic variant in a family. Hum Mutat 2011; 32: 568-71
40. Weiss RG, O'Connell KM, Flucher BE, Allen PD, Grabner M, Dirksen RT. Functional analysis of the R1086H malignant hyperthermia mutation in the DHPR reveals an unexpected influence of the III-IV loop on skeletal muscle EC coupling. Am J Physiol Cell Physiol 2004; 287: C1094-102
41. Eltit JM, Bannister RA, Moua O, et al. Malignant hyperthermia susceptibility arising from altered resting coupling between the skeletal muscle L-type Ca2+ channel and the type 1 ryanodine receptor. Proc Natl Acad Sci USA 2012; 109: 7923-8
42. Tong J, McCarthy TV,MacLennan DH. Measurement of resting cytosolic Ca2+ concentrations and Ca2+ store size in HEK-293 cells transfected with malignant hyperthermia or central core disease mutant Ca2+ release channels. J Biol Chem 1999; 274: 693-702
43. Yang T, Ta TA, Pessah IN, Allen PD. Functional defects in six ryanodine receptor isoform-1 (RyR1) mutations associated withmalignant hyperthermia and their impact on skeletal excitation-contraction coupling. J Biol Chem2003; 278: 25722-30
44. Ellis FR, Halsall PJ, Christian AS. Clinical presentation of suspected malignant hyperthermia during anaesthesia in 402 probands. Anaesthesia 1990; 45: 838-41
45. Forrest KM, Foulds N, Millar JS, et al. RYR1-related malignant hyperthermia with marked cerebellar involvement-A paradigm of heat-induced CNS injury? Neuromuscul Disord 2015; 25: 138-40
46. Tong J, Oyamada H, Demaurex N, Grinstein S, McCarthy TV, MacLennan DH. Caffeine and halothane sensitivity of intracellular Ca2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease. J Biol Chem 1997; 272: 26332-9
47. Lynch PJ, Tong J, Lehane M, et al. A mutation in the transmembrane/ luminal domain of the ryanodine receptor is associated with abnormal calcium release channel function and severe central core disease. Proc Natl Acad Sci USA 1999; 96: 4164-9
48. Tong J, McCarthy TV,MacLennan DH. Measurement of resting cytosolic Ca2+ concentrations and Ca2+ store size in HEK-293 cells transfected with malignant hyperthermia or central core disease mutant Ca2+ release channels. J Biol Chem 1999; 274: 693-702
49. Sambuughin N, Nelson T, Jankovic J, et al. Identification and functional characterisation of a novel ryanodine receptor mutation causing malignant hyperthermia in North American and South American families. Neuromuscul Disord 2001; 11: 530-7
50. Oyamada H, Oguchi K, Saitoh N, et al. Novel mutations in C-terminal channel region of the ryanodine receptor in malignant hyperthermia. Jpn J Pharamcol 2002; 88: 159-66
51. Yang T, Ta TA, Pessah IN, Allen PD. Functional defects in six ryanodine receptor isoform-1 (RyR1) mutations associated with malignant hyperthermia and their impact on skeletal excitation-contraction coupling. J Biol Chem 2003; 278: 25722-30
52. Brinkmeier H, Krämer J, Krämer R, et al. Malignant hyperthermia causing Gly2435Arg mutation of the ryanodine receptor facilitates ryanodine-induced calcium release in myotubes. Br J Anaesth 1999; 83: 855-61
53. Wehner M, Rueffert H, Koenig F, Neuhaus J, Olthoff D. Increased sensitivity to 4-chloro-m-cresol and caffeine in primarymyotubes frommalignant hyperthermia susceptible individuals carrying the ryanodine receptor 1 Thr2206Met (C6617T) mutation. Clin Genet 2002; 62: 135-46
54. Richter M, Schleithoff L, Deufel T, Lehmann-Horn F, Hermann-Frank A. Functional characterisation of distinct ryanodine receptor mutation in human malignant hyperthermia susceptible muscle. J Biol Chem 1997; 272: 5256-60
55. Girard T, Urwyler A, Censier K, Mueller C, Zorzato F, Treves S. Genotype-phenotype comparison of the Swiss malignant hyperthermia population. Hum Mut 2001; 18: 357-8
56. Tilgen N, Zorzato F, Halliger-Keller B, et al. Identification of four novel mutations in the C-terminal membrane spanning domain of the ryanodine receptor 1: association with central core disease and alteration of calcium homeostasis. Hum Mol Genet 2001; 10: 2879-87